Apilimod

A PIKfyve kinase inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

Supporting references

Contradictory references

AI-suggested references

Clinical trials

Apilimod is a PIKfyve kinase inhibitor with immunomodulatory, anti-proliferatory and antiviral activities (Gayle et al., 2017; Nelson et al., 2017).

Apilimod on DrugBank
Apilimod on PubChem
Apilimod on Wikipedia

Link	Tested on	Impact factor	Notes	Publication date
Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19 Preprint In vitro Screening	HeLa-ACE2 cells			Jun/16/2020
Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing Small molecule In vitro Screening	Vero E6 cells	42.78		Jul/24/2020
Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2 Small molecule In vitro	SVG-A cells; VERO E6 cells; SARS-CoV-2 strain 2019-nCoV/USA-WA1/2020	9.41	Inhibits SARS-CoV-2 release into cell from endosomes in an in vitro model, likely through PIKfyve kinase inhibition and consequent cathepsin maturation impairment. Inhibits VERO E6 cells infection by authentic SARS-CoV-2.	Aug/06/2020

Link	Publication date
The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19	Jun/16/2021
Low rotational barriers for the most dynamically active methyl groups in the proposed antiviral drugs for treatment of SARS-CoV-2, apilimod and tetrandrine.	May/08/2021
Discovery of SARS-CoV-2 Antivirals through Large-scale Drug Repositioning	Sep/25/2020
Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease	Aug/18/2021

ID	Title	Status	Phase	Start date	Completion date
NCT04446377	A Study of LAM-002A for the Prevention of Progression of COVID-19	Recruiting	Phase 2	Jul/15/2020	Apr/30/2021
Alternative id - LAM-002A-CVD-CLN01 Interventions - Drug: Apilimod Dimesylate Capsule\|Other: Placebo Study type - Interventional Study results - No Results Available Locations - Yale University, New Haven, Connecticut, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 142 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Viral Load Change\|Safety and Tolerability\|Clinical Efficacy\|Change in COVID-19 Clinical Status\|Oxygen Saturation